FDA document outlines apparent agency support for full approval of Biogen, Eisai's Leqembi
JUNE 7, 2023
On Wednesday, that vision came into better focus as the FDA released a document showing how the agency views the drug. . | As Alzheimer's partners Eisai and Biogen lay the groundwork for a wider launch of Leqembi, their efforts center on winning a full FDA approval.
Let's personalize your content